Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma
Authors:
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Practical Radiation Oncology
- Vol. 6 (5) , e149-e154
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trialThe Lancet Oncology, 2013
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage LevelsJNCI: Journal of the National Cancer Institute, 2013
- Positron Emission Tomography/Computed Tomography in the Staging and Treatment of Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Assessing the impact of FDG-PET in the management of anal cancerRadiotherapy and Oncology, 2008
- FDG-PET/CT in the evaluation of anal carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Positron Emission Tomography for Pretreatment Staging and Posttreatment Evaluation in Cancer of the Anal CanalMolecular Imaging and Biology, 2005
- Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcomeRadiotherapy and Oncology, 2001
- Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patientsCancer, 1994
- Cancer of the anal canal. Model for preoperative adjuvant combined modality therapyThe American Journal of Medicine, 1985
- Combined therapy for cancer of the anal canalDiseases of the Colon & Rectum, 1981